352 Results

People

  1. Straus
    Straus
  2. Zelenetz
    Zelenetz
  3. Noy
    Noy
  4. Horwitz
    Horwitz
  5. Moskowitz
    Moskowitz
  6. Matasar
    Matasar
  7. Portlock
    Portlock
  8. Hamlin
    Hamlin
  9. Moskowitz
    Moskowitz
  10. Palomba
    Palomba

Groups

  1. Center for Hematologic Malignancies (352)
  2. Department of Medicine (352)
  3. Hematologic Malignancies, Division of (352)
  4. Lymphoma (352)
  5. Survivorship Research (158)
  6. Population Sciences Research Program (124)
  7. Radiation Oncology, Department of (84)
  8. Epidemiology and Biostatistics (74)
  9. Executive Committee, Center for Hematologic Malignancies (72)
  10. Radiology, Department of (71)
  1. "Center for Hematologic Malignancies"
  2. "David Straus"
Formats
  1. Journal Article (163)
  2. Meeting Abstract (162)
  3. Book Section (15)
  4. Conference Paper (5)
  5. Research Letter (3)
  6. Editorial (2)
  7. Correspondence (1)
  8. Review (1)
Groups
  1. Center for Hematologic Malignancies (352)
  2. Department of Medicine (352)
  3. Hematologic Malignancies, Division of (352)
  4. Lymphoma (352)
  5. Survivorship Research (158)
  6. Population Sciences Research Program (124)

More Groups

People
  1. David Straus (352)
  2. Andrew Zelenetz (158)
  3. Ariela Noy (134)
  4. Paul Hamlin (117)
  5. Steven Horwitz (117)
  6. Craig Moskowitz (116)

More People

Years
  1. 2024 (2)
  2. 2023 (9)
  3. 2022 (13)
  4. 2021 (27)
  5. 2020 (25)
  6. 2019 (21)

More Years

Publications
  1. Blood (113)
  2. Journal of Clinical Oncology (43)
  3. Hematological Oncology (19)
  4. Cancer (14)
  5. Leukemia and Lymphoma (13)
  6. British Journal of Haematology (11)

More Publications

Publishers
  1. American Society of Hematology (119)
  2. American Society of Clinical Oncology (45)
  3. Wiley Blackwell (36)
  4. Elsevier Inc. (22)
  5. Taylor & Francis Group (14)
  6. John Wiley & Sons (12)

More Publishers

Results (352)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
    Research Letter

    Crosswell, H. E.; LaCasce, A. S.; Bartlett, N. L.; Straus, D. J.; Savage, K. J.; Zinzani, P. L.; Collins, G. P.; Fanale, M.; Fenton, K.; Dong, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Improved overall survival in stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Collins, G. P.; Ansell, S. M.; Straus, D. J.; Connors, J. M.; Dlugosz-Danecka, M.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D.; Bartlett, N.; Burke, J. M.; Lynch, R. C.; Domingo‐Domenech, E.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save